Overexpression of Rho GDP-dissociation inhibitor alpha predicts poor survival in oral squamous cell carcinoma

Oral Oncology

Volumn 47, Issue 6, 2011, Pages 452-458

  Chiang, Wei Fan ^a,b   Ho, Hsu Chueh ^c   Chang, Hua Yuan ^d   Chiu, Chien Chih ^d   Chen, Yuh Ling ^e   Hour, Tzyh Chyuan ^d   Chuang, Shu Ju ^d   Wu, Yu Jen ^f   Chen, Hau Ren ^g   Chen, Jen Hao ^d   Liu, Shyun Yeu ^a   Lu, Chin Li ^a   Chen, Jeff Yi Fu ^d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f MEIHO UNIVERSITY   (Taiwan)

^g NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Non cancerous matched tissues; Oral squamous cell carcinoma; Prognostic biomarker; Proteomics; RhoGDI ; Survival

Indexed keywords

BIOLOGICAL MARKER; GUANOSINE DIPHOSPHATE; RHO KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CELL MEMBRANE; CLINICAL ARTICLE; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; SQUAMOUS CELL CARCINOMA; TISSUE SECTION; UPREGULATION; VALIDATION STUDY;

ADULT; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MEMBRANE; CYTOPLASM; FEMALE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TAIWAN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79958037261     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.03.025     Document Type: Article

References (29)

1. Boureux A, Vignal E, Faure S, Fort P. Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol 2007;24(1):203-16. (Pubitemid 46026295)
2. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007;29(4):356-70. (Pubitemid 46597867)
3. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000;348(Pt. 2):241-55.
4. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005;390(Pt. 1):1-9. (Pubitemid 41192225)
5. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008;9(9):690-701.
6. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2(2):133-42.
7. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87(6):635-44.
8. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003;9(17):6432-40. (Pubitemid 38031830)
9. Abiatari I, DeOliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA, et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 2009;8(6):1494-504.
10. Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, et al. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 2009;69(19):7851-9.
11. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000;18(6):519-25. (Pubitemid 32844253)
12. Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. Eur J Cancer 2010;46(7):1252-9.
13. Hu LD, Zou HF, Zhan SX, Cao KM. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep 2007;17(6):1383-9.
14. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008;99(8):1507-14.
15. Liu SY, Lu CL, Chiou CT, Yen CY, Liaw GA, Chen YC, et al. Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan. Oral Oncol 2010;46(4):276-82.
16. Woolgar JA, Scott J, Vaughan ED, Brown JS, West CR, Rogers S. Survival, metastasis and recurrence of oral cancer in relation to pathological features. Ann R Coll Surg Engl 1995;77(5):325-31.
17. Koike H, Uzawa K, Nakashima D, Shimada K, Kato Y, Higo M, et al. Identification of differentially expressed proteins in oral squamous cell carcinoma using a global proteomic approach. Int J Oncol 2005;27(1):59-67.
18. Lo WY, Tsai MH, Tsai Y, Hua CH, Tsai FJ, Huang SY, et al. Identification of overexpressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007;376(1-2):101-7. (Pubitemid 44880973)
19. Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 2006;27(7):1417-23.
20. Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics 2008;7(9):1639-50.
21. Chen JY, Chang YL, Yu YC, Chao CC, Kao HW, Wu CT, et al. Specific induction of the high-molecular-weight microtubule-associated protein 2 (hmw-MAP2) by betel quid extract in cultured oral keratinocytes: clinical implications in betel quid-associated oral squamous cell carcinoma (OSCC). Carcinogenesis 2004;25(2):269-76.
22. Tseng MY, Liu SY, Chen HR, Wu YJ, Chiu CC, Chan PT, et al. Serine protease inhibitor (SERPIN) B1 promotes oral cancer cell motility and is overexpressed in invasive oral squamous cell carcinoma. Oral Oncol 2009;45(9):771-6.
23. Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC, et al. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 2008;44(4):325-34.
24. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999;11(8):545-54. (Pubitemid 29255886)
25. Di-Poi N, Faure J, Grizot S, Molnar G, Pick E, Dagher MC. Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex. Biochemistry 2001;40(34):10014-22. (Pubitemid 32800108)
26. Lin Q, Fuji RN, Yang W, Cerione RA. RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol 2003;13(17):1469-79. (Pubitemid 37084047)
27. Gandhi PN, Gibson RM, Tong X, Miyoshi J, Takai Y, Konieczkowski M, et al. An activating mutant of Rac1 that fails to interact with Rho GDP-dissociation inhibitor stimulates membrane ruffling in mammalian cells. Biochem J 2004;378(Pt. 2):409-19. (Pubitemid 38367232)
28. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol 2010;12(5):477-83.
29. Zhao L, Wang H, Li J, Liu Y, Ding Y. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. J Proteome Res 2008;7(9):3994-4003.